Patents by Inventor Angelo Leone Lombardo

Angelo Leone Lombardo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE SILENCING
    Publication number: 20240139319
    Abstract: An engineered transcriptional modulator (ETM) comprising: (a) at least one epigenetic effector domain; operably linked to (b) an endonuclease.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 2, 2024
    Applicant: EPSILEN BIO S.R.L
    Inventors: Angelo Leone Lombardo, Alice Reschigna, Tania Baccega
  • COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION
    Publication number: 20240132855
    Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 25, 2024
    Inventors: Aron Brandon Jaffe, Noorussahar Abubucker, Yesseinia Anglero-Rodriguez, Vic Myer, Angelo Leone Lombardo, Martino Alfredo Cappelluti
  • Vector production
    Patent number: 11957747
    Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 16, 2024
    Assignees: Ospedale San Raffaele S.r.l., Fondazione Telethon ETS
    Inventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
  • Permanent Epigenetic Gene Silencing
    Publication number: 20230340471
    Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).
    Type: Application
    Filed: October 11, 2022
    Publication date: October 26, 2023
    Inventors: Luigi Naldini, Angelo Leone Lombardo, Angelo Amabile, Alessandro Migliara
  • SELECTION BY MEANS OF ARTIFICIAL TRANSACTIVATORS
    Publication number: 20220056484
    Abstract: A method for selecting genome edited cells and/or for enrichment of genome edited cells in a population of cells comprising: (a) introducing into a cell or a population of cells at least one first component, at least one second component and at least one third component; and (b) selecting the genome edited cells which transiently express or transiently upregulate a nucleotide sequence encoding a selector.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 24, 2022
    Inventors: Pietro Genovese, Samuele Ferrari, Angelo Leone Lombardo, Luigi Naldini, Martina Fiumara
  • VECTOR PRODUCTION
    Publication number: 20210346489
    Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.
    Type: Application
    Filed: January 7, 2021
    Publication date: November 11, 2021
    Inventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
  • Vector production
    Patent number: 10912824
    Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: February 9, 2021
    Assignees: Ospedale San Raffaele S.r.l., Fondazione Telethon
    Inventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
  • Permanent Epigenetic Gene Silencing
    Publication number: 20190032049
    Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).
    Type: Application
    Filed: October 23, 2015
    Publication date: January 31, 2019
    Inventors: Luigi Naldini, Angelo Leone Lombardo, Angelo Amabile, Alessandro Migliara
  • Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
    Patent number: 10117899
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: November 6, 2018
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele SRL, Fondazione Telethon
    Inventors: Pietro Genovese, Philip D. Gregory, Michael C. Holmes, Angelo Leone Lombardo, Luigi Naldini
  • VECTOR PRODUCTION
    Publication number: 20170165348
    Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.
    Type: Application
    Filed: July 13, 2015
    Publication date: June 15, 2017
    Inventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
  • Methods and compositions for targeted integration
    Patent number: 8936936
    Abstract: Disclosed herein are methods and compositions for targeted integration of one or more copies of a sequence of interest using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain and integrase defective lentiviral donor constructs.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: January 20, 2015
    Assignees: Sangamo BioSciences, Inc., Ospedale San Raffaele S.R.L.
    Inventors: Michael C. Holmes, Shuyuan Yao, Luigi Naldini, Angelo Leone Lombardo